Biomarkers in Nonalcoholic Fatty Liver DiseaseReportar como inadecuado

Biomarkers in Nonalcoholic Fatty Liver Disease - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Canadian Journal of Gastroenterology and Hepatology - Volume 28 2014, Issue 11, Pages 607-618


In Vitro Drug Safety and Biotechnology, Faculty of Medicine, University of Toronto, Canada

Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Canada

Division of Gastroenterology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada

Department of Internal Medicine, University of Toronto, Toronto, Ontario, Canada

Received 29 June 2014; Accepted 9 October 2014

Copyright © 2014 Hindawi Publishing Corporation. This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License CC BY-NC, which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes.


BACKGROUND: Nonalcoholic fatty liver disease NAFLD is a chronic liver condition characterized by insulin resistance, type 2 diabetes and fat accumulation in the liver that may cause hepatic inflammation and progressive scarring leading to nonalcoholic steatohepatitis NASH and irreversible liver damage cirrhosis. As a result, there has been increased recognition of the need to assess and closely monitor individuals for risk factors of components of NAFLD and NASH, as well as the severity of these conditions using biomarkers.

AIM: To review the biomarkers used to diagnose and define the severity of NAFLD and NASH.

METHODS: A comprehensive PubMed and Google Scholar literature search was performed using the terms “non-alcoholic fatty liver disease”, “non-alcoholic steatohepatitis”, as well as the name of each biomarker known to be used. Articles indexed between 2004 and 2014 were used. Each author read the publications separately and the results were discussed.

RESULTS: Biomarkers offer a potential prognostic or diagnostic indicator for disease manifestation, progression or both. Serum biomarkers, including total cholesterol, triglycerides, insulin resistance and C-peptide, have been used for many years. Emerging biomarkers, such as apolipoprotein A1, apolipoprotein B, leptin, adiponectin, free fatty acids, ghrelin and tumour necrosis factor-alpha, have been proposed as tools that could provide valuable complementary information to that obtained from traditional biomarkers. Moreover, markers of cell death and mitochondrial dysfunction cytokeratins represent powerful predictors of risk. For biomarkers to be clinically useful in accurately diagnosing and treating disorders, age-specific reference intervals that account for differences in sex and ethnic origin are a necessity.

CONCLUSIONS: The present review attempts to provide a comprehensive analysis of the emerging risk biomarkers of NAFLD and NASH, and to use the clinical significance and analytical considerations of each biomarker pointing out sentinel features of disease progression.

Autor: Manuela G Neuman, Lawrence B Cohen, and Radu M Nanau



Documentos relacionados